The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Kyowa Kirin; Pfizer
Research Funding - Roche
Travel, Accommodations, Expenses - Kyowa Kirin; Pfizer
Identification of a novel prognostic gene signature in a clear cell renal cell carcinoma (ccRCC) population using an integrated multi-study single-cell RNAseq dataset.
 
Samuel García-Esteve
No Relationships to Disclose
 
Natalia Jiménez
No Relationships to Disclose
 
Caterina Aversa
Research Funding - Janssen (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen; Janssen
 
Laura Ferrer-Mileo
No Relationships to Disclose
 
Marta Garcia de Herreros
No Relationships to Disclose
 
Laia Fernandez-Mañas
No Relationships to Disclose
 
Laura González-Aguado
No Relationships to Disclose
 
Carlota Rubio-Pérez
No Relationships to Disclose
 
Inés Cobo-Diego
No Relationships to Disclose
 
Manuel Mazariegos
No Relationships to Disclose
 
Aleix Prat
Employment - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Begoña Mellado-González
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Sanofi
Research Funding - Bayer; Janssen; Roche
Travel, Accommodations, Expenses - Janssen; Pfizer
 
Òscar Reig-Torras
Speakers' Bureau - Bayer; Bristol-Myers Squibb; IPSEN,; Janssen-Cilag; Pfizer; Sanofi
Travel, Accommodations, Expenses - IPSEN,